By physician referral or invitation only

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

To evaluate the efficacy of bemnifosbuvir (BEM) compared with placebo in reducing all-cause hospitalization or all-cause death in COVID-19 outpatients receiving only supportive care.

Age & Gender

18 years ~ 99 years
Male, Female

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Alamance, Chatham, Durham, Orange, Wake)

Additional Study Information

Principal Investigator

David Wohl
Medicine-Infectious Diseases

Study Type

Clinical or Medical
Interventional

Study Topics

COVID-19

IRB Number

23-1440

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.